Compare Stocks: APLM, RNA, IVVD, and TNXP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$27.53 -1.7%	$20.69	$5.08 ▼ $42.12	$61.51M	1.53	10,163 shs	1,517 shs
IVVD Invivyd	$0.83 -1.1%	$0.77	$0.53 ▼ $3.07	$246.12M	0.81	4.21 million shs	1.96 million shs
RNA Avidity Biosciences	$14.19 -2.8%	$12.73	$11.13 ▼ $16.77	$249.74M	N/A	151,608 shs	167,785 shs
TNXP Tonix Pharmaceuticals	$13.14 -1.7%	$12.11	$9.40 ▼ $31.55	$229.31M	1.74	518,008 shs	252,185 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	-1.71%	+3.50%	+59.32%	+93.19%	+557.83%
IVVD Invivyd	-1.08%	-14.36%	+36.66%	-19.81%	-20.58%
RNA Avidity Biosciences	-2.81%	+4.03%	+20.87%	+20.25%	-70.18%
TNXP Tonix Pharmaceuticals	-1.72%	-3.31%	+16.70%	+18.70%	-52.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$27.53 -1.7%	$20.69	$5.08 ▼ $42.12	$61.51M	1.53	10,163 shs	1,517 shs
IVVD Invivyd	$0.83 -1.1%	$0.77	$0.53 ▼ $3.07	$246.12M	0.81	4.21 million shs	1.96 million shs
RNA Avidity Biosciences	$14.19 -2.8%	$12.73	$11.13 ▼ $16.77	$249.74M	N/A	151,608 shs	167,785 shs
TNXP Tonix Pharmaceuticals	$13.14 -1.7%	$12.11	$9.40 ▼ $31.55	$229.31M	1.74	518,008 shs	252,185 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	-1.71%	+3.50%	+59.32%	+93.19%	+557.83%
IVVD Invivyd	-1.08%	-14.36%	+36.66%	-19.81%	-20.58%
RNA Avidity Biosciences	-2.81%	+4.03%	+20.87%	+20.25%	-70.18%
TNXP Tonix Pharmaceuticals	-1.72%	-3.31%	+16.70%	+18.70%	-52.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	1.00	Sell	N/A	N/A
IVVD Invivyd	2.33	Hold	$8.00	868.52% Upside
RNA Avidity Biosciences	2.29	Hold	$63.85	349.94% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	86.45% Upside

Current Analyst Ratings Breakdown

Latest APLM, RNA, IVVD, and TNXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	IVVD Invivyd	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$27.00
8/6/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$25.00
8/3/2026	RNA Avidity Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/28/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	$8.50M	7.13	N/A	N/A	($2.89) per share	-9.53
IVVD Invivyd	$53.43M	4.56	N/A	N/A	$0.61 per share	1.35
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	$12.54 per share	N/A
TNXP Tonix Pharmaceuticals	$13.11M	17.19	N/A	N/A	$12.96 per share	1.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/24/2026 (Estimated)
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
RNA Avidity Biosciences	N/A	-$2.15	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	11/9/2026 (Estimated)

Latest APLM, RNA, IVVD, and TNXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/13/2026	Q2 2026	RNA Avidity Biosciences	-$1.42	-$1.18	+$0.24	-$1.18	$0.67 million	$3.00 million
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	0.96	0.96
IVVD Invivyd	N/A	5.87	5.87
RNA Avidity Biosciences	N/A	8.73	8.73
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
IVVD Invivyd	70.36%
RNA Avidity Biosciences	N/A
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
IVVD Invivyd	12.25%
RNA Avidity Biosciences	3.83%
TNXP Tonix Pharmaceuticals	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	45	2.20 million	N/A	Not Optionable
IVVD Invivyd	100	294.76 million	258.65 million	Optionable
RNA Avidity Biosciences	190	17.11 million	16.45 million	Optionable
TNXP Tonix Pharmaceuticals	50	17.15 million	16.81 million	Not Optionable

APLM, RNA, IVVD, and TNXP Headlines

Recent News About These Companies

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

September 2 at 6:19 PM | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

September 2 at 8:14 AM | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

September 2 at 7:00 AM | globenewswire.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Acquires 2,000 Shares

September 1, 2026 | insidertrades.com

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock

August 31, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street Zen

August 29, 2026 | americanbankingnews.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen

August 29, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Bagger Acquires 1,000 Shares

August 25, 2026 | insidertrades.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) Director Purchases $12,600.00 in Stock

August 24, 2026 | marketbeat.com

Tonix Pharma Names CEO Seth Lederman Interim CMO

August 18, 2026 | tipranks.com

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

August 18, 2026 | marketbeat.com

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

August 17, 2026 | fool.com

Tonix Pharmaceuticals Earnings Call Highlights Surging TONMYA Momentum

August 12, 2026 | theglobeandmail.com

Tonix Pharmaceuticals: Stronger-Than-Expected Tonmya Launch, Expanded Market Access, and Advancing Pipeline Underpin Buy Rating

August 11, 2026 | tipranks.com

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

August 10, 2026 | markets.businessinsider.com

Tonix outlines TNX-4800 Phase II with ~3,300 participants while scaling TONMYA to ~150 reps by September

August 10, 2026 | seekingalpha.com

Tonix Pharmaceuticals Holding C (TNXP) Q2 FY2026 earnings call transcript

August 10, 2026 | finance.yahoo.com

Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal?

August 10, 2026 | kalkinemedia.comK

Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...

August 10, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Q2 Earnings Call Highlights

August 10, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results

August 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

APLM, RNA, IVVD, and TNXP Company Descriptions

Apollomics NASDAQ:APLM

$27.53 -0.48 (-1.71%)

As of 09/4/2026 03:57 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Invivyd NASDAQ:IVVD

$0.83 -0.01 (-1.08%)

As of 09/4/2026 04:00 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Avidity Biosciences NASDAQ:RNA

$14.19 -0.41 (-2.81%)

As of 09/4/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Tonix Pharmaceuticals NASDAQ:TNXP

$13.14 -0.23 (-1.72%)

As of 09/4/2026 04:00 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APLM, RNA, IVVD, and TNXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APLM, RNA, IVVD, and TNXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APLM, RNA, IVVD, and TNXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

APLM, RNA, IVVD, and TNXP Company Descriptions

Apollomics NASDAQ:APLM

Invivyd NASDAQ:IVVD

Avidity Biosciences NASDAQ:RNA

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APLM, RNA, IVVD, and TNXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APLM, RNA, IVVD, and TNXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APLM, RNA, IVVD, and TNXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

APLM, RNA, IVVD, and TNXP Company Descriptions

Apollomics NASDAQ:APLM

Invivyd NASDAQ:IVVD

Avidity Biosciences NASDAQ:RNA

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools